Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

The company, a spinoff from German group Eckert & Ziegler, achieved a market capitalization of 126.5 million euros ($139.7 million) at its listing price of 5.10 euros. However, shares fell below that ...

The US stock market opened lower on Wednesday, October 2, amid rising geopolitical tensions in the Middle East between Israel ...

If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...

The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

Sep. 10, 2024 — Phase separation, when molecules part like oil and water, works alongside oxygen diffusion to help memristors -- electrical components that store ... Electrically Modulated Light ...